Celanese Presents Innovative Uses of Controlled Release Excipient in Drug Delivery Devices
By Business Wire News
By Business Wire News
DALLAS & EDINBURGH, Scotland
Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will discuss the use of ethylene vinyl acetate (EVA) as a foamed excipient in controlled release biologic applications at the 2015 Controlled Release Society (CRS) Annual Meeting and Exposition July 26-29 in Edinburgh, Scotland.
Pharmaceutical researchers and manufacturers choose Celanese’s VitalDose® EVA product over next best alternatives because of its customizable release properties and ability to blend well with other polymers. Celanese’s controlled release EVA copolymers have been used in a wide range of pharmaceutical drug delivery applications, including transdermal, subcutaneous, ocular, intravaginal, buccal, intraoral, and rectal.
“EVA excipients are known to provide excellent controlled release properties for drug dosage forms for both conventional and biologic APIs. Our EVA excipient, VitalDose®, has been a proven and effective solution for many years,” said Christian Schneider, R&D laboratory manager at Celanese. “Now, Celanese brings the unique value proposition of foamed EVA excipients, an innovative dosage form that would be suited to advanced APIs, such as Class II and IV small molecules, biologics, growth factors and stem cells.”
Highlighting the company’s presence at CRS will be a presentation from Celanese product R&D laboratory manager Christian Schneider who will discuss the use of EVA in biologics during a soapbox presentation:
Title: “Foamed Polymer Excipients: Novel Way to Deliver Stem Cells, Growth Factors, and Biologics for Controlled Release Applications”
Date: Sunday, July 26, 2015 at 1:25 p.m.
Presenter: Christian Schneider, R&D Laboratory, Celanese
Celanese will exhibit its customizable controlled release pharmaceutical copolymer, VitalDose®, at booth number 604.
For more product information, please access these resources:
- VitalDose® Brochure
- EVA Foamed Excipient Whitepaper
- EVA in Oral Controlled Release Whitepaper
Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. With sales almost equally divided between North America, Europe and Asia, the company uses the full breadth of its global chemistry, technology and business expertise to create value for customers and the corporation. Celanese partners with customers to solve their most critical needs while making a positive impact on its communities and the world. Based in Dallas, Texas, Celanese employs approximately 7,500 employees worldwide and had 2014 net sales of $6.8 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.
All registered trademarks are owned by Celanese International Corporation or its affiliates.
This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or customers will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.
Jon Puckett, +1 972 443 4965
Media Relations – Global
W. Travis Jacobsen, +1 972 443 3750
Media Relations Asia (Shanghai)
Xinya (Tessy) Tao, +86 21 2032 7118
Media Relations Europe (Germany)
Jens Kurth, +49(0)69 45009 1574